The British government has accepted all 44 recommendations of a doctor-led commission on artificial intelligence in healthcare, committing itself to a regulatory system that follows products from development through clinical use.
The proposed framework is risk-based and proportional. A tool that performs an administrative function would not face the same scrutiny as software that influences a diagnosis or treatment decision. But the commission’s central point is that safety cannot be judged only at the moment of market entry. Models can change, data can drift and performance can differ across hospitals and patient groups.
The government’s response gives the Medicines and Healthcare products Regulatory Agency a central role. The regulator will expand its AI Airlock programme, which allows developers and public bodies to test how existing rules apply to novel products, and will prepare a delivery plan for the wider recommendations.
Among the harder questions are responsibility when a clinician relies on a flawed output, the evidence needed before deployment and the monitoring required after a system enters routine care. The commission also called for clearer coordination among regulators and for patients and medical staff to have a meaningful voice in decisions about adoption.
Acceptance of the recommendations is a policy commitment, not a complete body of enforceable rules. Individual measures will still require guidance, regulation or legislation. Their significance lies in the government’s choice of a continuing oversight model rather than a one-time approval process for software that may evolve after it reaches the NHS.
Official government announcement
